valu usd unless otherwis note
setup favor head result
view abl achiev cc revenu growth fourth
straight quarter guidanc ep high end guidanc
manag may opt keep guidanc exclud
fx intact maintain flexibl comp tougher
momentum four segment wit last year give us
confid current guidanc prove conserv
guidanc prove conserv forecast cc
revenu growth guidanc lead rang
ww revenu non-gaap ep forecast
includ fx headwind among four quarter
easiest year-over-year comp sinc hurrican maria advers
impact financi perform
estim line consensu strong
perform peer suggest upsid estim
cc hurrican maria neg impact
revenu growth comp easier revenu
growth cc estim segment cvg mitg
rtg dg like sourc upsid estim
brain therapi pain therapi diabet
currenc greater impact result
guidanc see offset sinc earn call
dollar strengthen around euro
yen therefor estim neg impact currenc
translat revenu toward higher end guidanc
headwind respect guidanc neg
fx impact revenu like increas
potenti ep impact stronger dollar off-set
hedg expens control
ebit margin improv y/i per guidanc
mdt oper margin non-gaap flat constant currenc
basi manag chose step spend sever clinic
program mute margin expans forecast
ebit margin cc improv bp year-
over-year comparison easier margin
impact hurrican maria voluntari recal specif lot
infus set use insulin pump
manag reaffirm guidanc exclud fx
guidanc organ revenu growth manag
comfort higher end non-gaap ep guidanc
sinc manag alreadi said comfort high
end cc revenu growth guidanc rang unlik lift
face tougher comp ep guidanc unlik chang
compani absorb fx headwind revenu ep
estim cc consensu
dissemin produc price prior trade day market close estimate unless otherwis note
forecast least organ growth cvg
rtg mitg expect grow around
diabet group higher rate believ around
guidanc impli ww revenu close
requir addit year estim
therapi innov contribut approxim half
revenu growth balanc come global expans
especi emerg market value-bas health care
tavr micra reveal linq remain key growth
driver cvg five high-growth market within cvg
tavr diagnost mid-teen follow endoven
atrial fibril lvad high single-digit low double-
digit plan introduc largest valv size
evolut mm potenti low-risk indic
enhanc micra convert dual-chamb
devic significantli expand potenti market next-
gener icm reveal linq ii also schedul launch
double-digit growth emerg market expect
continu em revenu increas
compris ww revenu forti percent em
revenu came greater china middl east
africa latin america switch indirect
direct distribut major impact em growth
margin also made infrastructur invest key
market enabl market access improv penetr
oper margin target appear realist lower
goal annual improv bp
bp increas everi year june investor
day enterpris excel program lie heart
achiev target accordingli ep growth target
also come cc includ modest
currenc volatil reason move away cc
ep guidanc fx exposur fulli hedg
sever currenc especi emerg market
becom larger compon revenu
bloomberg capit market estim upside/downside/target
price target base price-to-earnings multipl
ep y/i mdt current price-to-earnings multipl
ep estim around key assumpt
underli ep estim revenu growth
basi point oper margin
expans fiscal year excess free cash
flow dividend deploy primarili share
buy-back target price-to-earnings price-to-earnings ntm
averag share
upsid scenario base price-to-earnings multipl
cy ep key assumpt underli
ep estim revenu growth
achiev combin accret
superior perform key product categori tavr
leadless pace neurovascular neurosurgeri diabet
surgic innov basi point oper
margin expans
downsid scenario base price-to-earnings multipl
cy ep key assumpt underli ep
estim revenu growth
basi point oper margin expans
meaning share buy-back
setup favor result follow recent weak share
schedul report octob result tuesday novemb host
confer call et compani issu follow guidanc quarter
revenu growth cc fx expect reduc revenu
million guidanc lead rang billion ww revenu
segment level cvg growth around rtg mitg
diabet around rel growth rate report
cvg dg forecast lower rtg mitg higher
non-gaap ep includ fx headwind
exhibit revenu guidanc octob
revenu ep estim billion consensu estim
contribut million comparison cc revenu growth rate year-ago
quarter prior quarter respect hurrican maria
neg impact approxim basi point revenu growth geograph
estim similar growth intern
exhibit cc growth estim segment comparison prior quarter result
revenu end revenu high end revenu y/yrevenu estim world-wide excl fx y/ycardiac vascular rhythm heart structur heart peripher invas therapi gastrointestin therapi excl fx y/ycardiac vascular rhythm heart structur heart peripher invas therapi monitor therapi exhibit revenu model
respect fx dollar strengthen around euro
yen sinc compani earn call dollar gain
major trade currenc well therefor estim neg impact
currenc translat revenu toward higher end guidanc movement
exchang rate like affect guidanc discuss later report
exhibit chang valu dollar major trade currenc
geographi worldwidegeographi internationalgeographi worldwiderevenu pro-forma revenu growth y/ycontribut revenu growth intenational cardiac vascular vascular rhythm heart rhythm heart structur heart structur heart peripher peripher invas therapi invas therapi gastrointestin gastrointestin therapi therapi growth growth intenational excl revenu growth revenu market market medic suppli devic
achiev cc revenu growth fourth straight
last three quarter report constant currenc cc revenu
growth rate respect cc growth meaning
guidanc busi unit deliv upsid estim
coronari structur heart csh brain therapi pain therapi surgic
innov diabet five share common characterist midst
new product cycl abl sustain momentum csh one
three busi unit cardiac vascular group cvg brain therapi pain therapi
fall restor therapi group rtg surgic innov larger
constitu csh contribut double-digit sale growth past year
structur heart mdt sale growth market follow launch evolut
transcathet heart valv gain market share europ
last coupl quarter introduct new deliveri system enveo
favor influenc tavr sale growth launch resolut onyx japan
reviv growth coronari busi turnaround start
evolut resolut onyx pass first anniversari
rule possibl anoth posit surpris csh model cc sale growth
csh bp lower growth
revenu growth brain therapi high singl digit higher last
seven quarter last four doubl digit three product
categori within brain therapi neurovascular neurosurgeri princip drive
forc behind perform grew high teen help
adopt endovascular treatment ischem stroke neurovascular suit
imag navig robot ablat system neurosurgeri stealthstat
surgic navig system o-arm surgic imag system well
receiv revenu growth estim brain therapi vs
turnaround pain therapi fuel launch intelli spinal
cord stimul system along evolv workflow year ago commerci success
intelli enabl captur share one attract med-tech end-
market intelli introduc canada australia new zealand latin america
mdt busi grew y/i busi grew even
quickli estim sale growth pain therapi vs
sale growth surgic innov busi unit roughli two-third mitg
sale reliant shift open surgeri minim invas option portfolio
consist devic advanc advanc stapl advanc
sale increas doubl digit support enhanc ligasur vessel-s
instrument advanc stapl sale grew mid-singl digit led signia power
surgic stapl system tri-stapl reload believ surgic innov
maintain steadi mid-single-digit sale growth done sever quarter row
diabet group carri strong momentum last three quarter
growth driven minim minim
intern shortag sensor suppli resolv report
earn call train activ user system
number could easili increas last three month launch
 follow
europ way recent enter stand-alone continu glucos
launch guardian connect
manag mention call launch solid start sugar iq
assist avail guardian connect employ cognit comput capabl
watson give user person insight predict alert manag consid
featur key differenti rel cgm system market
mdt forecast sale growth dg lower growth last
quarter conserv guid view sinc demand remain healthi year-
over-year comp easi dg revenu fell
exhibit year-over-year revenu growth exclud fx four segment last four
quarter estim
ebit margin cc improv higher
mdt oper margin non-gaap flat constant currenc basi despit
approxim cc revenu growth includ benefit currenc hedg
program ebit margin increas basi point expens growth basi point
higher revenu growth extra spend direct primarili cvg diabet
group temper ebit margin growth expens least partial
discretionari natur give manag flexibl adjust spend necessari
year-over-year comparison easier margin impact
hurrican maria voluntari recal specif lot infus set use model
insulin pump therefor forecast oper margin improv
basi point exclud fx higher guidanc foundat
margin improv enterpris excel program approach first
anniversari coupl month enterpris excel encompass global oper
function optim commerci optim global oper single-
largest compon compris manufactur initi global oper
save sourc suppli chain initi
expect manag reaffirm guidanc revenu
growth exclud fx non-gaap ep
last updat guidanc earn call august increas
forecast organ revenu growth marin ep guidanc latter
unfavor shift exchang rate guidanc follow
organ revenu growth manag comfort higher end
rang fx expect headwind million includ fx
forecast revenu billion
segment level growth forecast cvg rtg mitg rang
dg low-to-mid teen
oper margin expect increas bp constant currenc basi
non-gaap ep fx expect neutral ep guidanc impli
y/i growth adjust asset sale even though revenu face big fx-
relat headwind gain deriv contract natur hedg elimin
neg impact ep
exhibit revenu ep guidanc
revenu end revenu high end revenu y/yrevenu end ep high end ep asset asset y/yep medic suppli devic
chang expect guidanc compani estim currency-
relat impact revenu ep guidanc organ revenu growth
remain manag comfort high end given
comp difficult neg impact currenc translat revenu
like increas million non-gaap ep may neg affect
penni fx forecast revis predict howev believ
manag abl off-set headwind expens manag
stronger revenu growth keep ep guidanc
revenu ep estim billion high end
guidanc revenu estim impli organ growth high end guidanc exhibit
diabet group like sourc upsid surpris rel estim
individu segment consensu estim billion
exhibit revenu model
geographi worldwidegeographi internationalgeographi worldwiderevenu pro-forma revenu growth y/ycontribut revenu growth intenational cardiac vascular vascular rhythm heart rhythm heart structur heart structur heart peripher peripher invas therapi invas therapi gastrointestin gastrointestin therapi therapi growth growth intenational excl revenu growth revenu medic suppli devic
exhibit estim vs consensu
varianc tableactualrbccm estimatesconsensu except ep fy rhythm heart structur peripher invas gi gross sg oper expens pre-tax medic suppli devic
price target base ep estim y/i mdt
current price-to-earnings multipl ep estim compar target multipl key
assumpt underli ep estim revenu growth
basi point oper margin expans compani realiz
benefit enterpris excel program place excess free cash flow
dividend deploy primarili share buy-back price target basi
outperform rate
risk rate price target
lacklust growth key franchis includ pace defibril system atrial
fibril tavr drug-elut stent surgic innov brain pain therapi spine
inabl achiev target cost save manag believ achiev billion
gross save end enterpris excel program
project save fail materi ep estim could risk
risk price target rate includ potenti regulatori delay reject
failur devic clinic trial weaken demand key market price pressur weak
util trend fx
lead world-wide medic technolog compani engag manufactur
sell device-bas medic therapi compani oper four segment cardiac
vascular group restor therapi group diabet group minim invas
million except ep fy april
